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P29 SINGAPORE CHILDHOOD CANCER SURVIVOR STUDY – A
MULTI-INSTITUTIONAL COLLABORATIVE STUDY ON LONG-
TERM SURVIVORS OF CHILDHOOD CANCER
L. Aung a,*, S.M. Sabai b, Y.H. Chan c. a Division of Pediatric
Hematology-Oncology, KK Womens and Childrens Hospital,
Singapore. b Division of Pediatric Hematology-Oncology, National
University Hospital System, Singapore. c Biostatistics Unit, Yong Loo
Lin School of Medicine, National University of Singapore, Singapore
Background: Worldwide, survival rates among childhood can-
cer patients are increasing; thus, assessing the risk of late effects
and complications is important.
Methods: The Singapore Childhood Cancer Registry (1981–2005)
included 704 patients from KK Womens and Childrens Hospital
and 626 from the National University Hospital (NUH). The Singa-
pore Childhood Cancer Survivor Study (SIN-CCSS) consisted of all
individuals who survived at least 2 or more years after treatment
for cancer diagnosed during childhood or adolescence.
Findings: A total of 1043 (72.4%) of 1440 patients are alive, of
which 839 (80.4%) are long-term survivors. 58.6% (n = 492) survi-
vors had haematological malignancies, whereas 41.4% (n = 347)
were diagnosed with various solid tumours. To date, 79 survivors
have enrolled in the study at NUH. Mean age was 14.9 years (range
4.9–31.8); 55.7% were male, 11.4% were an only child, 58.2% were
Singaporean, and 74.4% were Chinese. 27.8% continued to see the
doctor once or twice per year and 12.7% of these visits were
related to previous illness. Preliminary analysis shows that
21.8% of participants reported anxiety. Endocrine adverse effects
were most common (40.4%), followed by respiratory complaints
(37.9%).
Interpretation: At least 58% of those diagnosed with childhood
cancer are long-term survivors. This is the first study of its kind
in Singapore, looking at long-term survivors of childhood cancer
with a multicultural and multiethnic approach. In the future, we
plan to focus on prevention of late effects, aetiological (genetic
and environmental) and outcomes research, and survivor
education.
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P30 MICRORNA AS DIAGNOSTIC AND PROGNOSTIC MARKERS IN
HUMAN HEPATOCELLULAR CARCINOMAS
Y.-H. Huang a,*, C.-T. Yeh a,b. a Liver Research Center, Department of
Hepato-Gastroenterology, Chang Gung Memorial Hospital, Taipei,
Taiwan. b Molecular Medicine Research Center, Chang Gung
University, Taoyuan, Taiwan
Background: Human hepatocellular carcinomas (HCCs) are the
fifth most common malignant tumours worldwide, and the third
leading cause of cancer-related death. In view of the high postop-
erative recurrence rate, identification of potential biomarkers
should be considered; these can be a diagnostic marker, prognos-
tic marker, or target for cancer therapy. MicroRNAs (miRNAs)
have been proposed to contribute to oncogenesis because they
can function either as tumour suppressors or oncogenes.
Methods To search the useful index marker to predict postoper-
ative recurrence rate of patients with HCC, adjacent noncancer-
ous liver tissues from HCC patients with good prognosis (n = 6)
and poor prognosis (n = 6) were collected. 270 miRNA expression
profiles were analysed using a highly sensitive stem-loop reverse
transcriptase (RT)-PCR method.
Findings: 20 miRNA candidates were found that were associa-
tion with good and poor prognosis. Further screening of 216
adjacent non-cancerous liver tissues identified six miRNAs signif-
icantly correlated with disease-free survival (p < 0.021). Cox pro-
portional-hazards analysis revealed that high expression of
miR-A6 and miR-A18 were the most significant markers associ-
ated with poor disease-free survival (p = 0.013, hazard ratio [HR]
1.633 [95% CI 1.108–2.408]; p = 0.001, HR 1.929 [1.298–2.867],
respectively). High expression of miR-A3 and miR-A19 were the
most significant markers related to better disease-free survival
(p = 0.012, HR 0.431, 95% CI [0.224–0.830]; p = 0.001, HR 0.529,
[0.357–0.783], respectively). Additionally, in J7 cells transduced
with anti-miR-A6 lentivirus, cell-growth suppression was
observed and cell-cycle related molecules, including CDK2,
CDK4, cyclin E, and cyclin D1, were underexpressed.
Interpretation: miRNAs associated with good and bad prognosis
can serve as biomarkers for HCC.
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P31 EXPRESSION OF NEUROENDOCRINE MARKERS IN NON-
SMALL-CELL LUNG CARCINOMAS AND ASSOCIATION WITH
POST-OPERATIVE SURVIVAL
N. Naseem a,*, A.H. Nagi a, N. Reyaz b, M. Ashraf b, W. Sami a.
a University of Health Sciences, Khayaban-e-Jamia Punjab, Lahore,
Pakistan. b Gulab Devi Chest Hospital, Lahore, Pakistan
Introduction: Neuroendocrine differentiation has been sug-
gested as a marker of poor prognosis in 10–30% of non-small-cell
lung carcinomas (NSCLCs). We studied immunohistochemical
expression of the neuroendocrine markers chromogranin A
(CgA), synaptophysin (SYN), histidine decarboxylase (HDC), and
neuron-specific enolase (NSE) in various subtypes of NSCLCs,
and noted whether there was any association with post-operative
survival.
Methods: 225 patients (mean age 45 years) diagnosed with
NSCLCs were surgically treated at Gulab Devi Chest Hospital,
Lahore, Pakistan from January, 2004, to January, 2006. Relevant
clinical and laboratory data including age, sex, tumour location,
and type of surgical procedure were recorded in separate profor-
mas. After haematoxylin and eosin staining, paraffin-embedded
tissue blocks of tumour specimens were stained immunohisto-
chemically with monoclonal anti-CgA, anti-SYN, anti-HDC, and
anti-NSE antibodies. A total of 153 patients were followed up for
4.5 years, and the shortest follow-up time was 13 months. COX
proportional-hazard multivariate analysis was applied to observe
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the relationship between the NSCLC neuroendocrine markers and
post-operative survival.
Findings: The subtypes of NSCLCs included in the study were
54% squamous-cell carcinomas (SCCs), 32.5% adenocarcinomas,
and 11.5% large-cell lung carcinomas (LCLCs). 10.2%, 17.3%,
15.1%, and 7.4% of NSCLC tissue demonstrated focal to almost dif-
fuse strong cytoplasmic staining of the tumour cells with CgA,
SYN, HDC, and NSE, respectively. Assessing individual subtypes
showed that 3.8%, 5.1%, 6.5%, and 1.8% SCCs, 13.3%, 17.3%, 20%,
and 9% adenocarcinomas, and 21.3%, 28%, 33%, and 16.6% LCLCs
demonstrated positive staining with CgA, SYN, HDC, and NSE,
respectively. HDC expression was stronger and more sensitive
than CgA, SYN, and NSE (p = 0.0063). Multivariate analysis showed
that the NSCLC patients with neuroendocrine markers had signif-
icantly shorter survival (p = 0.031). The following factors were
related to survival: lung-cancer histological differentiation
(p = 0.0057), clinical stage (p = 0.001), and neuroendocrine markers
reaction (p = 0.072).
Interpretation: Neuroendocrine markers in NSCLC are signifi-
cantly associated with cancer-cell differentiation and post-opera-
tive survival. These markers should be applied clinically as
prognostic factors for post-operative survival of NSCLC patients.
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P32 EXPRESSION OF BCL-2 ONCOPROTEIN IN WOMEN OF
REPRODUCTIVE AGE WITH UTERINE SMOOTH-MUSCLE
TUMOURS IN PAKISTAN
N. Naseem *, A.H. Nagi, S. Butt. University of Health Sciences,
Khayaban-e-Jamia Punjab, Lahore, Pakistan
Background: BCL-2 oncoprotein has an important role in cell
development, maturation, and replication by reducing the
requirement for growth factors, and acts as an anti-apoptotic fac-
tor in various neoplastic processes. This study investigated
immunohistochemical expression of BCL-2 protein in uterine
leiomyomas, smooth-muscle tumours of uncertain malignant
potential (STUMP), and leiomyosarcomas (LMS), in female
patients of child-bearing age. The correlation between BCL-2
expression and various clinicopathological parameters was
assessed to evaluate its prognostic value.
Methods: A total of 66 female patients (mean age 37 years, SD
4.5) presenting with uterine leiomyomas (n = 42), STUMP (n = 18),
and LMS (n = 6) from July, 2005, to July, 2006, at the departments
of Gynecology and Obstetrics in tertiary-care hospitals in Lahore,
Pakistan, were included. Paraffin-embedded tissues of these
patients were subjected to BCL-2 immunohistochemistry. Find-
ings were compared and correlated with different clinicopatho-
logical parameters. Clinical information, including follow-up
data until July, 2010, was obtained from the database of the
hospitals.
Findings: Positive BCL-2 immunostaining was observed in two
of six patients with LMS, 11 of 18 with STUMP, and 39 of 42 with
leiomyomas. Frequency of BCL-2 expression and staining inten-
sity were significantly different between LMS and leiomyoma
(p < 0.05), as well as STUMP and leiomyoma (p < 0.05), but not
between LMS and STUMP (p > 0.05). No significant association
was found between BCL-2 immunostaining and tumour size,
age, menstrual history, parity, infertility, contraceptive measures,
or family history of neoplasms. Patients with uterine LMS who
had BCL-2 positive tumours showed less vascular-space involve-
ment and longer overall survival than patients with BCL-2 nega-
tive tumours (p < 0.05).
Interpretation: Expression of BCL-2 oncoprotein is more fre-
quent and strong in leiomyomas than in LMS and STUMP. Stron-
ger BCL-2 expression in benign leiomyomas and the better
clinical outcome of BCL-2-positive LMS indicate that this protein
is a good prognostic factor. Larger studies are needed to establish
BCL-2 as a routine marker for improved prognosis in malignant
uterine smooth-muscle tumours.
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P33 PREDICTION OF PATHOLOGICAL GRADE OF ASTROCYTO-
MAS USING MRI – A NEW METHOD VERSUS CLINICIAN
PERFORMANCE
Z. Zhao, M. He*, C. Wu, K. Lan, J. Xiao, Y. Zhang, L. Jia. West China
Hospital and West China School of Medicine, Sichuan University,
Chengdu Sichuan, China
Background: Astrocytoma is the most common glioma and has
poor prognosis, affected by treatment strategy and pathological
grading. Pre-operative assessment of grades is difficult. The aim
of this study was to evaluate a support vector machine (SVM)
model to help clinicians predict grading of astrocytomas.
Methods: 106 patients were recruited at our hospital between
January, 2008, and April, 2009. Two clinicians read MRIs and
scored the appearance of astrocytomas, and a support vector
machine (SVM) model was constructed. From clinicians predic-
tions, predictions of the SVM model, and predictions of clinicians
with the SVM model, three receiver operating characteristic (ROC)
curves were created to discriminate low-grade and high-grade
groups.
Findings: The area under the curve (AUC) for clinicians predic-
tions was 0.7881, which was significantly less than the AUC for
the SVM model (0.9370, v2 8.62, p = 0.0033) and the AUC for clini-
cians with the SVM model (0.8829, v2 13.46, p = 0.0002). However,
the AUCs of the SVM model and clinicians with the SVM model
did not differ significantly (v2 1.63, p = 0.2011).
Interpretation: The SVM model is a useful mathematical
method that can help clinicians improve the accuracy of predict-
ing pathological grade of astrocytomas.
Funding: None.
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